stockrowCaris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Return on invested capital
Caris Life Sciences,�Inc.'s return on invested capital over the twelve months to 30 September 2026 was 22.2%, up 4.2 percentage points from fiscal 2025 (18.1%). That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 18.1% | 18.05 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 61.8% |
| KRYS Krystal Biotech, Inc. compare | 27.2% |
| CAI Caris Life Sciences,�Inc. | 22.2% |
| TGTX TG Therapeutics, Inc. compare | 10.7% |
| IBRX ImmunityBio, Inc. compare | 0.00% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −1,480.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement